| Literature DB >> 33364968 |
Ling Zhou1, Jie Deng1, Sarah L Stenton2,3, Ji Zhou1, Hua Li1, Chunhong Chen1, Holger Prokisch1,2,3, Fang Fang1.
Abstract
We present two unrelated Chinese patients with CAD deficiency manifesting with a triad of infantile-onset psychomotor developmental delay with regression, drug-refractory epilepsy, and anaemia with anisopoikilocytosis. Timely translation into uridine supplementation, within 2-months of disease onset, allowed us to stop conventional anti-epileptic drugs and led to dramatic improvement in the clinical symptoms, with prompt cessation of seizures, resolution of anaemia, developmental progress, and prevention of development of severe and non-reversible manifestations. The remarkable recovery and prevention of advanced disease with prompt treatment, highlights the need to act immediately upon genetic diagnosis of a treatable disease. This further reinforces CAD deficiency as a treatable neurometabolic disorder and emphasises the need for a biomarker or genetic new born screening for early identification.Entities:
Keywords: CAD deficiency; anaemia with anisopoikilocytosis; developmental delay; epilepsy; uridine
Year: 2020 PMID: 33364968 PMCID: PMC7750521 DOI: 10.3389/fphar.2020.608737
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810